Clinical Trial Update: Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes? [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether Fiasp offers prolonged time in range compared with Asp for children with type 1 diabetes; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Asp (regular insulin)
• Fiasp (insulin aspart)

Snippet

Sponsor: Medical University of Warsaw | Conditions: Diabetes type1, Diabetes Mellitus, Type 1 | Phase 4 | Status: UNKNOWN